Advertisement
Research ArticleViewpoint

Could a Nebulized or Dry Powder Inhalation of a Dopamine D1R Agonist Be a Treatment of Idiopathic Pulmonary Fibrosis?

Bradley T. Andresen
Journal of Pharmacology and Experimental Therapeutics September 2023, 386 (3) 274-276; DOI: https://doi.org/10.1124/jpet.123.001661

Article Information

vol. 386 no. 3 274-276
DOI 
https://doi.org/10.1124/jpet.123.001661
PubMed 
37591657
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received March 8, 2023
  • Accepted April 7, 2023
  • Published online August 17, 2023.
Copyright & Usage 
Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Bradley T. Andresen
  1. Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California
  1. Address correspondence to:
    Dr. Bradley T. Andresen, FAHA, Western University of Health Sciences, College of Pharmacy, Pharmaceutical Sciences Department, 309 E. Second St., Pomona, CA 91766-1854. E-mail: bandresen{at}westernu.edu

Statistics from Altmetric.com

Article usage

Article usage: August 2023 to September 2024

AbstractFullPdf
Aug 20230300106
Sep 2023032387
Oct 202305717
Nov 202305518
Dec 20230419
Jan 202402511
Feb 202406611
Mar 202401717
Apr 202404614
May 20240259
Jun 20240139
Jul 20240148
Aug 202401411
Sep 2024065

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleViewpoint

D1DR Agonists for IPF

Bradley T. Andresen
Journal of Pharmacology and Experimental Therapeutics September 1, 2023, 386 (3) 274-276; DOI: https://doi.org/10.1124/jpet.123.001661
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement